COVID-19
COVID-19 vaccine eligibility creates challenges for UK pharmacies
October 8, 2025Medical Communications COVID-19, NHS, pharmacies, vaccinations
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments despite no longer meeting the …
Mental health medicine use in England reaches record high, NHSBSA report reveals
July 29, 2025Manufacturing and Production, Medical Communications, Research and Development ADHD, COVID-19, NHS Business Services Authority, Psychiatry, antidepressants, antipsychotics, anxiolytics, barbiturate, dementia, hypnotics, mental health
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions in England have reached their …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
July 16, 2025Medical Communications COVID-19, Spikevax, US Food and Drug Administration, Vaccine, Virology
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, Spikevax, in children aged six …
Study links COVID-19 and some vaccines to increased risk of rare neurological condition
June 5, 2025Medical Communications, Medical Education, Medical/ Scientific Writing, Research and Development COVID-19, COVID-19 vaccine, Guillain-Barré Syndrome (GBS), Neurology, Virology, adenoviral vector vaccines, mRNA-based vaccines, medical study, neurological condition
An international study has found an increased risk of Guillain-Barré syndrome (GBS) following SARS-CoV-2 infection and after vaccination with adenoviral …
EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention
July 1, 2024Research and Development COVID-19, EMA, Infections and infestations, coronavirus
AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for sipavibart under the …
AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug
May 17, 2024Research and Development AstraZeneca, COVID-19, Immunology, clinical trial
AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 pre-exposure prophylaxis treatment, sipavibart (formerly …
Sanofi and Novavex sign exclusive $1.2bn licensing agreement to co-commercialise COVID-19 vaccine and develop flu-COVID-19 vaccines
May 10, 2024Sales and Marketing COVID-19, COVID-19 vaccine, Immunology, Novatex, Sanofi, flu-COVID-19 vaccine, licensing agreement
French pharma and healthcare company Sanofi and US biotech Novavex, have entered into a co-exclusive licensing agreement for a number …
AstraZeneca withdraws COVID-19 vaccine Vaxzevria
May 9, 2024Sales and Marketing AstraZeneca, COVID-19, Immunology, thrombosis with thrombocytopenia syndrome
UK-based pharmaceutical company AstraZeneca has announced that is it voluntarily withdrawing its COVID-19 vaccine Vaxzevria due to a drop in …
Gilead’s Veklury recommended by NICE for COVID-19 treatment
April 9, 2024Medical Communications COVID-19, Gilead Sciences, Infections and infestations, remdesivir
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has recommended the use of Veklury …
NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19
January 12, 2024Medical Communications COVID-19, Infections and infestations, NICE
The National Institute for Health and Care Excellence (NICE) has announced that it has expanded the guidance around which patients …
Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine
October 5, 2023Research and Development COVID-19, Immunology, Moderna, clinical trial, influenza, vaccines
Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational combination vaccine against influenza and …
ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial
September 5, 2023Research and Development ACM Biolabs, COVID-19, Immunology, SARS-CoV-2, Vaccine, clinical trial
ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an adjuvanted booster vaccine for SARS-CoV-2, …
The NIH’s RECOVER initiative could lead to the first official treatment for long COVID-19
August 1, 2023Research and Development COVID-19, Infections and infestations, NIH, clinical trials, long covid
As of 31 July 2023, The National Institutes of Health (NIH) launched the first trials of its ‘Researching COVID to …
Moderna files for FDA authorisation for updated COVID-19 vaccine
June 23, 2023Research and Development COVID-19, FDA, Immunology, Moderna, Vaccine
Biotechnology company Moderna has announced that it has completed submission of a regulatory application to the US Food and Drug …
FDA approves first oral antiviral to treat adult patients with COVID-19
May 26, 2023Medical Communications COVID-19, FDA, Infections and infestations, paxlovid
The US Food and Drug Administration (FDA) has announced that it has approved the oral antiviral Paxlovid (nirmatrelvir tablets and …
